

1 **A Machine Learning Model Incorporating Laboratory Blood Tests Discriminates Between SARS-CoV-2**  
2 **and Influenza Infections at Emergency Department Visit**

3 Junyi Liu<sup>1</sup>, Lars F. Westblade<sup>2,3,4</sup>, Amy Chadburn<sup>2,3</sup>, Richard Fideli<sup>2,3</sup>, Arryn Craney<sup>2,3</sup>, Sophie Rand<sup>2</sup>,  
4 Melissa Cushing<sup>2,3</sup>, Zhen Zhao<sup>2,3</sup>, Jingjing Meng<sup>1\*</sup>, He S. Yang<sup>2,3\*</sup>

5

6 <sup>1</sup>Department of Computer Science and Engineering, University of Buffalo, Buffalo, NY, USA

7 <sup>2</sup>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA

8 <sup>3</sup>New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA

9 <sup>4</sup>Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA

10

11

12 \*Joint corresponding authors

13 Correspondence to:

14 He S. Yang, PhD

15 Department of Pathology and Laboratory Medicine

16 Weill Cornell Medicine

17 525 E. 68th Street, Suite F 707, New York, NY 10065

18 Email: [hey9012@med.cornell.edu](mailto:hey9012@med.cornell.edu)

19 Phone: 212-746-6292

20 Jingjing Meng, PhD

21 Department of Computer Science and Engineering

22 University of Buffalo

23 304 Davis Hall, Buffalo. NY

24 Email: [Jmeng2@buffalo.edu](mailto:Jmeng2@buffalo.edu)

25 Phone: 716-645-0566

26

27

28 **Key words:** SARS-CoV-2, COVID-19, influenza, machine learning, random forest, routine laboratory tests

29 **Abbreviation:** AGAP: anion gap, COVID-19: corona virus disease-2019; SARS-CoV-2: severe acute

30 respiratory syndrome coronavirus 2; TAT: turn-around time; ED: emergency department; RT-PCR: real-

31 time reverse transcription polymerase chain reaction; WBC: white blood cells; RBC: red blood cells;

32 RDW-CV: Red blood cell distribution width; BUN: Blood urea nitrogen; MCV: Mean corpuscular volume;

33 AUC: Area under the receiver operating characteristic curve; NYPH/WCM: New York Presbyterian

34 Hospital/Weill Cornell Medicine; NYPH/LMH: New York Presbyterian Hospital/Lower Manhattan

35 Hospital.

36 **Running title:** Model discriminates COVID-19 and influenza

37 Word count: 2417

38

39



41 **Abstract**

42 **Introduction:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus are  
43 contagious respiratory pathogens with similar symptoms but require different treatment and  
44 management strategies. This study investigated whether laboratory blood tests can discriminate  
45 between SARS-CoV-2 and influenza infections at emergency department (ED) presentation.

46 **Methods:** 723 influenza A/B positive (2018/1/1 to 2020/3/15) and 1,281 SARS-CoV-2 positive  
47 (2020/3/11 to 2020/6/30) ED patients were retrospectively analyzed. Laboratory test results completed  
48 within 48 hours prior to reporting of virus RT-PCR results, as well as patient demographics were included  
49 to train and validate a random forest (RF) model. The dataset was randomly divided into training (2/3)  
50 and testing (1/3) sets with the same SARS-CoV-2/influenza ratio. The Shapley Additive Explanations  
51 technique was employed to visualize the impact of each laboratory test on the differentiation.

52 **Results:** The RF model incorporating results from 15 laboratory tests and demographic characteristics  
53 discriminated SARS-CoV-2 and influenza infections, with an area under the ROC curve value 0.90 in the  
54 independent testing set. The overall agreement with the RT-PCR results was 83% (95% CI: 80-86%). The  
55 test with the greatest impact on the differentiation was serum total calcium level. Further, the model  
56 achieved an AUC of 0.82 in a new dataset including 519 SARS-CoV-2 ED patients (2020/12/1 to  
57 2021/2/28) and the previous 723 influenza positive patients. Serum calcium level remained the most  
58 impactful feature on the differentiation.

59 **Conclusion:** We identified characteristic laboratory test profiles differentiating SARS-CoV-2 and  
60 influenza infections, which may be useful for the preparedness of overlapping COVID-19 resurgence and  
61 future seasonal influenza.

62

63

64 **Introduction:**

65 Both the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiology agent of  
66 coronavirus disease 2019 (COVID-19), and influenza virus are contagious respiratory pathogens, which  
67 cause as a wide range of illnesses from asymptomatic or mild through to severe disease and death.<sup>1</sup>  
68 However, the fraction of severe infection cases, as well as the mortality rate, is higher in COVID-19 than  
69 in influenza.<sup>2</sup> Transmissibility, estimated by the basic reproductive rate ( $R_0$ ), is also higher in SARS-CoV-2  
70 ( $R_0 \sim 2.5$ ) compared to influenza ( $R_0 \sim 1.7$ ).<sup>3</sup> The SARS-CoV-2 and influenza virus infections have similar  
71 symptoms, such as cough, sore throat, fever, fatigue, and myalgias, making clinical differentiation at  
72 hospital presentation challenging without the aid of laboratory tests. Currently, the detection of these  
73 pathogens relies on viral specific real-time reverse-transcription polymerase chain reaction (RT-PCR)  
74 testing of nasopharyngeal swabs or other upper respiratory track specimens.<sup>4</sup> However, while the turn-  
75 around time (TAT) of RT-PCR testing is usually within a day, it can be substantially longer due to reagent  
76 shortages<sup>5</sup> as experienced during the COVID-19 pandemic, or lack of on-site testing, particularly in many  
77 of the smaller and more rural hospitals. Since the treatment of SARS-CoV-2 and influenza is different,  
78 delayed identification of infected patients may result in inappropriate patient management and  
79 increased risk of infection for healthcare personnel. Therefore, rapid discrimination of SARS-CoV-2 and  
80 influenza infections, and identification of high-risk patients is vital for individual patient care and for  
81 controlling disease transmission.

82 Routine laboratory tests provide objective and quantifiable characterization of the effects of the virus on  
83 the human body<sup>6</sup>. Routine test results are generally available within 1-2 hours and are accessible prior to  
84 patient discharge from the emergency department (ED). Previous studies<sup>7, 8</sup>, including our own  
85 publications<sup>9</sup>, have demonstrated that machine learning models incorporating routine laboratory blood  
86 tests and demographics can differentiate and predict SARS-CoV-2 infected and non-infected patients.  
87 Machine learning algorithms have the capability of revealing complicated pattern or trend behind high-

88 dimensional laboratory data that are challenging for human eyes to visualize. So far, limited studies have  
89 investigated the differences in laboratory blood test results between SARS-CoV-2 and influenza  
90 infections<sup>3,10</sup>. While no single laboratory test strongly associates with SARS-CoV-2 or influenza infection,  
91 we investigated whether a combination of multiple routine laboratory tests can discriminate between  
92 these two viral infections at an early stage of disease, and aimed to find out the most impactful  
93 laboratory features that contribute to the discrimination. Furthermore, COVID-19 has been evolving  
94 since the initial outbreak of the disease<sup>11</sup>. We are interested in understanding whether the impactful  
95 laboratory features remain unchanged in more recent COVID-19 positive patients during the 2020-2021  
96 winter wave.

97

98

99 **Methods**

100 Patient cohorts

101 We reviewed retrospectively laboratory and demographic data of 723 influenza A/B positive patients  
102 from January 1, 2018 to March 15, 2020, and 1,281 SARS-CoV-2 positive patients from March 11, 2020  
103 to June 30, 2020, evaluated in the ED of a New York City academic hospital. Routine influenza RT-PCR  
104 testing was suspended from March to September 2020 to prioritize resources for SARS-CoV-2 testing.  
105 The SARS-CoV-2 cohort included infected patients from the initial outbreak as well as from the post-  
106 apex phase. Influenza or SARS-CoV-2 RT-PCR results, routine laboratory testing results within 2 days  
107 prior to the completion of RT-PCR testing, and patient demographic information were obtained from the  
108 laboratory information system (Cerner Millennium, Cerner Corporation). Exclusion criteria included  
109 patients < 18 years of age, and patients who lacked laboratory test results within the designated time  
110 window (within 2 days prior to RT-PCR results release). In total, the final dataset included results from  
111 1,237 SARS-CoV-2 RT-PCR positive patients and 513 influenza positive (393 type A, and 119 type B, 1  
112 A/B) ED patients (**Figure 1**). This study was approved by the Institutional Review Board (IRB) of Weill  
113 Cornell Medicine and deemed IRB exempt by the University of Buffalo.

114 From December 1, 2020 to February 28, 2021, there were a total of 559 SARS-CoV-2 RT-PCR positive  
115 patients and only 1 influenza RT-PCR positive patient (this patient was also positive for SARS-CoV-2) who  
116 were evaluated in the ED of our hospital. After applying the exclusion criteria as state above, 519 SARS-  
117 CoV-2 positive patients were included in the new dataset. Since there were only 1 positive influenza  
118 case during the same time, we had to compare the new SARS-CoV-2 dataset to the previous influenza  
119 dataset from 2018/1/1 to 2020/3/11.

120

121

122 Model construction

123 A total of 57 chemistry, hematology, and coagulation tests commonly ordered in these patients were  
124 examined in the SARS-CoV-2 and influenza cohorts. Of them, 15 laboratory tests were selected to be  
125 included in the model based on two criteria: 1) a result available for at least 70% of the patients within  
126 48 hours before a specific SARS-CoV-2 RT-PCR test and 2) showing a significant difference (P-value after  
127 Bonferroni correction less than 0.05) between influenza and SARS-CoV-2 positive patients. After the  
128 feature selection, a 22-dimensional vector (15 laboratory tests, one age, one gender, five race variables  
129 (African American, Asian, Caucasian, others and unknown) was constructed to represent every SARS-  
130 CoV-2 or influenza RT-PCR test result (**Figure 2**). If one laboratory test was ordered multiple times within  
131 48 hours, an average of the values was calculated and used for analysis. The missing value of a specific  
132 laboratory test in a feature vector was imputed by the mean value of the available non-missing values of  
133 that dimension over all patients. Subsequently, a random forest classifier model was developed  
134 incorporating the results of 15 selected laboratory tests and patient age, gender, and race, using the  
135 Python scikit-learn package 0.23.2. The whole data set was randomly split into a training set (2/3 of  
136 cases) and a testing set (1/3 cases) with the same ratio of SARS-CoV-2/influenza cases as the ratio for  
137 the overall cases. The hyperparameters of random forest model was trained using 5-fold cross  
138 validation, where all RT-PCR tests in the training set were randomly partitioned into 5 equal buckets  
139 with the same SARS-CoV-2/influenza ratio. The random forest model was then trained using selected  
140 hyperparameters with all RT-PCR tests in the training set. The performance of the model was evaluated  
141 in the independent testing set using area under the receiver operating characteristic curve (ROC),  
142 sensitivity, specificity, and agreement with RT-PCR. The Shapley Additive Explanations (SHAP) technique  
143 was employed to visualize the impact of each laboratory test on the differentiation.

144

145



146 **Results:**

147 Patients with SARS-CoV-2 infection were significantly older (median: 64 years, IQR: 51-75) than those  
148 with influenza (median: 48 years, IQR: 32-63,  $p < 0.001$ ). The percentage of male patients was also  
149 significantly higher in SARS-CoV-2 cohort (58.36%) than in the influenza group (41.33%,  $p < 0.001$ ). In  
150 addition, a significantly lower percentage of African American was present in the SARS-CoV-2 group than  
151 the influenza cohort ( $p = 0.02$ , **Table 1**).

152 The laboratory results completed within 48 hours prior to a positive SARS-CoV-2 or influenza RT-PCR  
153 test result were included in the analysis. A total of 15 laboratory test results with missing rate  $< 30\%$   
154 were found to be significantly different between the SARS-CoV-2 and influenza infected patients at their  
155 ED presentation. The performance of the random forest model incorporating these 15 laboratory tests  
156 and patient age, sex and race achieved an area under the ROC curve (AUC) value of 0.90 (95% CI: 0.88-  
157 0.93) in the independent testing set. The overall agreement with the RT-PCR, determined at the  
158 Youden's index point, was 83% (95% CI: 80-86%), with 87% (95% CI: 84-90%) agreement with SARS-CoV-  
159 2 RT-PCR results and 73% (95% CI: 66-80%) agreement with the influenza RT-PCR results. The random  
160 forest model generated a probability score, from 0 to 1, to differentiate influenza vs. SARS-CoV-2  
161 infection (cutoff 0.58 at the Youden' index point).

162 In order to visualize and interpret the impact of each laboratory test to the overall differentiation, a  
163 Shapley Additive Explanations (SHAP) technique (Version 4.10.0) was employed which assigns each  
164 feature a value of importance (the SHAP value) for the differentiation of SARS-CoV-2 or influenza  
165 infections. A summary plot is shown in **Figure 2**, in which the impact of each laboratory test and  
166 demographic feature was ordered from high to low. Notably, serum calcium level had the greatest  
167 impact on the differentiation of these two infections. The SARS-CoV-2 patients demonstrated  
168 significantly lower serum calcium concentrations than the influenza positive patients. In addition, the  
169 peripheral monocyte and basophil counts were significantly lower whereas the lymphocyte and white

170 blood cell counts were significantly higher in the SARS-CoV-2 patients compared to the influenza  
171 patients. The SARS-CoV-2 patients also demonstrated hypochloremia, hyperglycemia, higher  
172 BUN/creatinine ratio and higher anion gap compared to the influenza patients.

173 Since the COVID-19 has been evolving since the initial outbreak, we further investigated whether our  
174 random forest model is still discriminative between SARS-COV-2 and influenza in the 2020-2021 winter  
175 wave and whether the top laboratory tests are still impactful on the differentiation. From December 1,  
176 2020 to February 28, 2021, there were a total of 559 SARS-CoV-2 RT-PCR positive patients evaluated in  
177 the ED of our hospital, and among them, 519 were included in our dataset after the exclusion criteria  
178 was applied (Demographic information in **Table 1**). However, there was only one positive influenza case  
179 identified in the ED during this time period, and this patient was also positive for SARS-CoV-2 RT-PCR  
180 testing. Therefore, we test our model on the new SARS-CoV-2 dataset with the previous 723 influenza  
181 A/B positive patients from January 1, 2018 to March 15, 2020. The random forest model with the same  
182 parameters achieved an AUC of 0.82 with an overall agreement of 74% (95% CI: 71-77%) using the same  
183 cutoff value. Agreement with SARS-CoV-2 and influenza RT-PCR results was 75% and 73%, respectively.

184 Interestingly, serum calcium level remains the most impactful laboratory feature on the differentiation  
185 of SARS-CoV-2 and influenza infections (**Figure 3**). Compared to the influenza positive patients, the more  
186 recent SARS-CoV-2 positive patients still exhibited hypocalcemia, lower level of monocyte counts, and  
187 higher levels of lymphocyte, WBC, and neutrophil counts as well as higher anion gap and BUN/creatinine  
188 ratio.

189

190

191 **Discussion:**

192 This retrospective analysis illustrates that a combination of 15 laboratory tests, along with patient  
193 demographics, can help distinguish between SARS-CoV-2 and influenza infections at an early stage of  
194 disease. While SARS-CoV-2 and influenza infections show similar symptoms<sup>2</sup>, each has a characteristic  
195 laboratory test result profile that could be used for early disease differentiation and prediction.

196 Although the level of seasonal influenza was extremely low in the U.S. and other countries in the  
197 northern hemisphere during the past winter<sup>12, 13</sup>, our findings pave the way for future research about  
198 the distinct pathophysiological mechanisms underlying SARS-CoV-2 and other respiratory virus  
199 infections, and may be useful for the preparedness of overlapping COVID-19 resurgence and future  
200 seasonal influenza. Understanding the characteristic laboratory profiles associated with the two  
201 pathogens may assist early and rapid identification of high-risk patients and optimize resource use  
202 during periods of high infection rates for both SARS-CoV-2 and influenza, especially in areas where  
203 hospitals or clinics do not have onsite RT-PCR testing for respiratory viruses.

204 Machine learning models can perform analysis of massive quantities of data and extract hidden patterns  
205 that that would be challenging for human eyes to identify. A machine learning classification model  
206 should make clinical and biologic sense. Here we report that in our machine learning classification  
207 model, the serum total calcium level, among all routine laboratory tests, has the highest impact on the  
208 differentiation of SARS-CoV-2 from influenza infections. Hypocalcemia has been previously reported as a  
209 prevalent biochemical abnormality in SARS-CoV-2 infected patients with a marked negative influence on  
210 disease severity, biochemical inflammation and thrombotic markers<sup>14</sup>, and has been proposed as an  
211 independent risk factor for hospitalization due to COVID-19<sup>15</sup>. While the exact underlying biologic  
212 mechanism for hypocalcemia in SARS-CoV-2 infection is still unclear, it may be closely associated with  
213 viral-associated multi-organ damage and increase in inflammatory cytokines<sup>16</sup>. Studies better  
214 delineating the mechanism and impact of viral infections on calcium metabolism may suggest

215 therapeutic modalities in the future. In addition, SARS-CoV-2 patients exhibited lower monocyte and  
216 basophil counts, higher white blood cell, neutrophil and lymphocyte counts, as well as hypochloremia,  
217 hyperglycemia, higher BUN/creatinine ratio and higher anion gap, compared to influenza positive  
218 patients. The substantial differences in laboratory result profile between SARS-CoV-2 and influenza  
219 patients shed new lights on the reactions of human body to the two types of viral infections, which may  
220 contribute to the different disease manifestations and outcomes.

221 The COVID-19 winter wave in New York was not as severe as the devastating first wave that hit the city  
222 in March and April 2020. The number of hospitalized patients as well as the mortality rates were lower  
223 than those of the first wave<sup>17</sup>. More patients showed mild or asymptomatic disease, which may partly  
224 explain why it was more difficult to differentiate SARS-CoV-2 and influenza infections from laboratory  
225 test results and why the performance of our model with the same parameters has dropped in the new  
226 dataset. The performance of the model can be improved with a continuous learning process that  
227 involves model updating and parameter optimizing using the new data. Interestingly, despite the  
228 evolvement of COVID-19, the laboratory features that have greatest impact on the differentiation  
229 between the two viral infections have been stable in the longitudinal datasets.

230 A study limitation is that our model's performance has not been validated in a dataset including  
231 concurrent SARS-CoV-2 and influenza positive patients as Influenza RT-PCR testing was suspended from  
232 March to September 2020 to prioritize resources for SARS-CoV-2 testing. We attempted to collect new  
233 data from November 2020 to February 2021, however, there was only one influenza positive case during  
234 this time in our hospital ED. This observation was consistent with the extremely low level of seasonal  
235 influenza in North America<sup>12</sup>. Despite a lack of direct comparison, the characteristic profile of SARS-CoV-  
236 2 in comparison to influenza infection is still valid and has the potential to impact patient care. The  
237 performance of our model could be further improved when it is trained with more concurrent influenza  
238 and SARS-CoV-2 patient data.

239 **Conclusion:**

240 The proposed random forest model incorporating age, gender, race and 15 routine laboratory tests can  
241 discriminate between SARS-CoV-2 and influenza infection during an initial patient ED visit. We identified  
242 15 routine laboratory blood tests, which assist in separating of SARS-CoV-2 from influenza infection,  
243 with serum calcium level being the most impactful feature. These characteristic laboratory test result  
244 profiles associated with SARS-CoV-2 and influenza infections mirror the biologic effects of these viruses  
245 on patients and provides clinically an opportunity for early identification of high-risk patients. Our  
246 analysis demonstrates the utility of machine learning as an emerging technique to support the diagnosis  
247 of infectious diseases.

248

249

250

251

252 **Author contribution:**

253 JL for performing data analysis and manuscript editing; LFW for providing influenza data and manuscript  
254 editing; AC for manuscript editing; RF for organizing laboratory test results for COVID-19 and influenza  
255 patients; AC for manuscript editing; SR for providing COVID-19 data; MC and ZZ for manuscript editing;  
256 JM for supervision of data analysis and manuscript editing; HSY for conceptualization, project  
257 supervision, data analysis, and writing and editing of the manuscript.

258

259 **Conflict of Interest Disclosure:**

260 None of the authors have conflict of interest in this project.

261 **Funding:**

262 There is no funding source for this study.

263

264

265

266 Table 1. Demographic of SARS-CoV-2 and influenza patient cohorts

| <b>Demographics:</b>     | SARS-CoV-2 positive patients from 2020/3/11 to 2020/6/30 (n = 1,237) | Influenza positive patients from 2018/1/1 to 2020/3/15 (n = 513) | SARS-CoV-2 positive patients from 2020/12/1 to 2021/2/28 (n =519) |
|--------------------------|--|--|---|
| Age, years; median (IQR) | 64 (51-75)   | 48 (32-63) <sup>*#</sup>   | 61 (45-73)  |
| Gender, male, n (%)      | 722 (58.36%)   | 212 (41.33%) <sup>*#</sup>                                       | 253 (48.75%)  |
| Race:                    |  |  |   |
| Asian                    | 52 (4.20%)   | 32 (6.24%)   | 33 (6.36%)  |
| African American         | 117 (9.46%)  | 66 (12.87%) <sup>*</sup>   | 71 (13.68%)   |
| White                    | 324 (26.19%)   | 153 (29.82%) <sup>#</sup>  | 21 (40.66%)   |
| Other                    | 213 (17.22%)   | 128 (24.95%) <sup>*#</sup>                                       | 93 (17.92%)   |
| Unknown                  | 531 (42.93%)   | 134 (26.12%) <sup>*#</sup>                                       | 111 (21.39%)  |


267 <sup>\*</sup>p value < 0.05 between SARS-CoV-2 positive patients from 2020/3/11 to 2020/6/30 and influenza  
 268 positive patients from 2018/1/1 to 2020/3/15.

269 <sup>#</sup>p value < 0.05 between SARS-CoV-2 positive patients from 2020/12/1 to 2021/2/28 and influenza  
 270 positive patients from 2018/1/1 to 2020/3/15.

271

272


273 **Figure 1**



274



275 Figure 2




276

277

278

279 **Figure 3.**



280

281 **Figure legends:**

282 Figure 1: Inclusion/exclusion cascade of SARS-CoV-2 and influenza patient cohorts in the dataset.

283 Figure 2: Impact of each laboratory test and demographic feature to the overall differentiation of SARS-

284 CoV-2 and influenza infections in the random forest model. Dataset includes SARS-CoV-2 positive

285 patients from 2020/3/15 to 2020/6/30, and influenza positive patients from 2018/1/1 to 2020/3/11.

286 Laboratory tests are organized on the y-axis according to their impact from high to low. Individual values

287 of each test for each patient are colored according to their relative values. Higher and lower values are

288 shown in red and blue, respectively. Absolute SHAP values of each test are shown on the x-axis. Positive

289 SHAP value to the right indicates prediction of SARS-CoV-2 whereas negative SHAP value to the left

290 indicates prediction of influenza.

291 Figure 3: Impact of each laboratory test and demographic feature to the overall differentiation in the

292 new SARS-CoV-2 dataset from 2020/12/1 to 2021/2/28 and the previous influenza dataset from

293 2018/1/1 to 2020/3/11.

294

295 References

- 296 1. World Health Organization (WHO). Coronavirus disease (COVID-19): Similarities and differences  
297 with influenza. URL: [https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-  
298 similarities-and-differences-with-influenza](https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-similarities-and-differences-with-influenza). 2020.
- 299 2. Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza  
300 pandemics. *Lancet Infect Dis*. 2020;20:e238-e244.
- 301 3. Manzanares-Meza LD, Medina-Contreras O. SARS-CoV-2 and influenza: a comparative overview  
302 and treatment implications. *Bol Med Hosp Infant Mex*. 2020;77:262-273.
- 303 4. Centers for Disease Control and Prevention (CDC). Overview of testing for SARS-CoV-2 (COVID-  
304 19); URL: [https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-  
305 overview.html#TestingInfection](https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html#TestingInfection). Accessed June 8, 2021.
- 306 5. American Society of Microbiology. Shortages of COVID-19 and other testing supplies identified  
307 by ASM's data collection tool. URL: [https://asm.org/Press-Releases/2020/October/Shortages-of-  
308 COVID-19-and-Other-Testing-Supplies-I](https://asm.org/Press-Releases/2020/October/Shortages-of-COVID-19-and-Other-Testing-Supplies-I). Accessed on May 26, 2021.
- 309 6. Yang HS, Hou Y, Zhang H et al. Machine learning highlights down-trending of COVID-19 patients  
310 with a distinct laboratory profile. *Health Data Science*. 2021; Article ID 7574903. Doi:  
311 10.34133/7574903.
- 312 7. Bayat V, Phelps S, Ryono R, et al. A SARS-CoV-2 Prediction Model from Standard Laboratory  
313 Tests. *Clin Infect Dis*. 2020; ciaa1175. doi: 10.1093/cid/ciaa1175.
- 314 8. Joshi RP, Pejaver V, Hammarlund NE, et al. A predictive tool for identification of SARS-CoV-2  
315 PCR-negative emergency department patients using routine test results. *J Clin Virol*.  
316 2020;129:104502.
- 317 9. Yang HS, Hou Y, Vasovic LV, et al. Routine Laboratory Blood Tests Predict SARS-CoV-2 Infection  
318 Using Machine Learning. *Clin Chem*. 2020;66:1396-1404.

- 319 **10.** Song X, Delaney M, Shah RK, Campos JM, Wessel DL, DeBiasi RL. Comparison of Clinical Features  
320 of COVID-19 vs Seasonal Influenza A and B in US Children. *JAMA Netw Open*. 2020;3:e2020495.
- 321 **11.** Singh D, Yi SV. On the origin and evolution of SARS-CoV-2. *Exp Mol Med*. 2021;53:537-547.
- 322 **12.** Olsen SJ, Azziz-Baumgartner E, Budd AP, et al. Decreased Influenza Activity During the COVID-19  
323 Pandemic - United States, Australia, Chile, and South Africa, 2020. *MMWR Morb Mortal Wkly*  
324 *Rep*. 2020;69:1305-1309.
- 325 **13.** Jones N. How COVID-19 is changing the cold and flu season. *Nature News Feature* 2020. URL:  
326 <https://www.nature.com/articles/d41586-020-03519-3>. Accessed June 8, 2020.
- 327 **14.** Di Filippo L, Doga M, Frara S, Giustina A. Hypocalcemia in COVID-19: Prevalence, clinical  
328 significance and therapeutic implications. *Rev Endocr Metab Disord*. 2021; doi: 10.1007/s11154-  
329 021-09655-z.
- 330 **15.** Di Filippo L, Formenti AM, Rovere-Querini P, et al. Hypocalcemia is highly prevalent and predicts  
331 hospitalization in patients with COVID-19. *Endocrine*. 2020;68:475-478.
- 332 **16.** Zhou X, Chen D, Wang L, et al. Low serum calcium: a new, important indicator of COVID-19  
333 patients from mild/moderate to severe/critical. *Biosci Rep*. 2020; 40(12): BSR20202690.
- 334 **17.** Lewis C DJ. Why New York's last COVID surge was far less deadly than its first. *Gothamist*. URL:  
335 <https://gothamist.com/news/why-new-yorks-last-covid-surge-was-far-less-deadly-than-its-first>.  
336 Last accessed: June 28, 2021. 2021.  
337